^
Association details:
| Biomarker: | P2RY8-CRLF2 fusion + JAK2 QGinsR683 |
|---|---|
| Cancer: | Childhood B Acute Lymphoblastic Leukemia |
| Drug: | Jakafi (ruxolitinib) (JAK2 inhibitor, JAK1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia
Published date:
10/25/2012
Excerpt:
We, therefore, investigated the efficacy of the JAK inhibitor ruxolitinib and the mTOR inhibitor rapamycin in xenograft models of 8 pediatric B-ALL cases with and without CRLF2 and JAK genomic lesions….Three JAK2m/CRLF2R ALL xenografts (I, II, III), including the sample harboring a P2RY8-CRLF2 fusion, exhibited significantly decreased leukemia burden with ruxolitinib treatment compared with vehicle, evidenced by lower peripheral blast count (Figure 1A) and splenic blast count...
DOI:
https://doi.org/10.1182/blood-2012-03-415448
